ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1398

Inflammatory Arthritis DMARD Adverse Effects Are Pervasive and Can Greatly Impact Quality of Life and Work and Social Roles: Initial Results from the Omeract Safety Working Group

Kathleen M. Andersen1, Ayano Kelly2, Anne Lyddiatt3, Clifton O. Bingham III4, Vivian P. Bykerk5, Marita Cross6, Adena Batterman7, Joan Westreich8, Lyn March9, Michelle Jones10, Beverly Shea11, Peter Tugwell12, Peter Brooks13, Lee S. Simon14, Robin Christensen15 and Susan J. Bartlett16, 1Department of Family Medicine, McGill University, Montreal, QC, Canada, 2Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia, 3Musculoskeletal Group, Cochrane Collaboration, Hamilton, ON, Canada, 4Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 5Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, 6Institute of Bone and Joint Research–Kolling Institute, University of Sydney, Sydney, Australia, 7Social Work Programs, Hospital for Special Surgery, New York, NY, 8Department of Social Work Programs, Hospital for Special Surgery, New York, NY, 9Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, 10Johns Hopkins University School of Medicine, Baltimore, MD, 11University of Ottawa, Ottawa, ON, Canada, 12Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, 13The University of Melbourne, Victoria, Australia, 14SDG LLC Consulting, West Newton, MA, 15Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, 16Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Adverse events, doctor-patient relationship, drug safety, patient-reported outcome measures and qualitative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: There is suboptimal reporting of adverse events (AE) in trials. The OMERACT Safety Working Group is developing a patient-centered AE collection and reporting approach to complement existing methods. Our initial goal was to hear from inflammatory arthritis (IA) patients about their perspectives on the benefit-harm balance of DMARDs.

Methods: Using an interview schedule, experienced interviewers conducted focus groups with IA patients in the US (n=14), Canada (n=10), and Australia (n=15) that were recorded, transcribed, and analyzed using a pragmatic thematic analysis approach based in grounded theory.

Results: Almost all patients reported AE ranging from mild to severe. The majority learn to live with AE, but some lives were completely changed.

“It was like I was domiciled on the toilet…I couldn’t go anywhere because you never knew when you needed a toilet.” (M 60s, CA)

“I’m on MTX and I’m finally friends with it. It took 2 years…I feel normal…except med day…But I’m happy to give up half a day…to have my life.” (F 20s, USA)

Many patients reported making adjustments to diet, sleep, and lifestyle to address AEs. Patients used different complementary and alternative approaches to self-manage their AEs but continued to live with ongoing disruption of function, self-confidence, work, and social roles due to AE.

“I feel like I can’t think anymore, and that really affects my work. And that’s my biggest problem. I can push through the pain and… fatigue, but I can’t think clearly. I just can’t do my job.” (F 30s USA)

The cumulative burden of AEs often led to patient-initiated discontinuation.

“I would open the fridge and look at the little brown envelope that the syringes were in. The nausea would start just looking at the envelope… I took it for a few more years, but I just couldn’t stand it anymore. It’s just like, get me off of this stuff.” (M 70s CA)

Underreporting was common due to embarrassment and uncertainty whether and how to discuss AEs. Providers were often perceived to react with disinterest, minimization, or irritation. Long-term safety was less concerning to patients with longer IA duration who had more symptoms and decreased function but greater treatment benefits despite repeated drug failures and serious AE.

Conclusion: The prevalence and importance of AEs, especially “nuisance AEs” is viewed differently by patients and clinicians. AEs negatively impacted function, participation, and QOL. Acceptability, tolerability and self-management of SEs varied among patients, by drug type and life stage, and in response to disrupted social and work roles. Patients learned to underreport SE when they perceived disinterest/minimization by clinicians.


Disclosure: K. M. Andersen, None; A. Kelly, Bristol Myers Squibb, 2; A. Lyddiatt, None; C. O. Bingham III, None; V. P. Bykerk, None; M. Cross, None; A. Batterman, None; J. Westreich, None; L. March, None; M. Jones, None; B. Shea, None; P. Tugwell, None; P. Brooks, None; L. S. Simon, None; R. Christensen, None; S. J. Bartlett, UCB, Inc., 5,Lilly, 5,Pfizer, Inc., 5,Novartis, 5.

To cite this abstract in AMA style:

Andersen KM, Kelly A, Lyddiatt A, Bingham III CO, Bykerk VP, Cross M, Batterman A, Westreich J, March L, Jones M, Shea B, Tugwell P, Brooks P, Simon LS, Christensen R, Bartlett SJ. Inflammatory Arthritis DMARD Adverse Effects Are Pervasive and Can Greatly Impact Quality of Life and Work and Social Roles: Initial Results from the Omeract Safety Working Group [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/inflammatory-arthritis-dmard-adverse-effects-are-pervasive-and-can-greatly-impact-quality-of-life-and-work-and-social-roles-initial-results-from-the-omeract-safety-working-group/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-arthritis-dmard-adverse-effects-are-pervasive-and-can-greatly-impact-quality-of-life-and-work-and-social-roles-initial-results-from-the-omeract-safety-working-group/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology